Aller au contenu principal
Accès ouvert déclaré 2026 article

Prevalence and Associated Factors of Metabolic Dysfunction-Associated Steatotic Liver Disease Across Obesity Metabolic Phenotypes in Chronic Schizophrenia

0Citations signalées — pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Background: Chronic schizophrenia patients often present with exacerbated clinical symptoms and higher rates of fatty liver disease. This study is designed to compare the occurrence rates of metabolic dysfunction-associated steatotic liver disease (MASLD) and associated factors among hospitalized chronic schizophrenia patients with different obesity metabolic phenotypes. Methods: ) and metabolic health profile, resulting in four distinct obesity metabolic phenotypes: metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO). Their sociodemographic information, biochemical and lipid parameters were retrospectively collected. Results: In this study, we found that the occurrence rate of metabolic dysfunction-associated steatotic liver disease (MASLD) among chronic schizophrenia patients with prolonged hospitalization was 54.6%. Within the MHNO grouping, MASLD-positive and MASLD-negative subgroups showed significant differences in key metabolic indicators, diabetes status, antipsychotic polypharmacy, and triglyceride-glucose-body mass index (TyG-BMI). Logistic regression analysis demonstrated that Antipsychotic polypharmacy (OR=2.656, P=0.007, 95% CI=1.299-5.429) and TyG-BMI (OR = 1.043, P <0.001, 95% CI = 1.029-1.057) were independently associated with MASLD in the MHNO group. Conclusion: Metabolic dysfunction-associated steatotic liver disease is prevalent among chronic schizophrenia patients, with a notable prevalence gradient across obesity metabolic phenotypes. For metabolically healthy non-obese chronic schizophrenia patients, the importance of regular metabolic dysfunction-associated steatotic liver disease screening cannot be overlook ed.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Prevalence and Associated Factors of Metabolic Dysfunction-Associated Steatotic Liver Disease Across Obesity Metabolic Phenotypes in Chronic Schizophrenia
Date Crossref
01/08/2026
Éditeur
Informa UK Limited
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Liver Disease Diagnosis and TreatmentSchizophrenia research and treatmentTryptophan and brain disorders

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.